Download PDF
Semin Thromb Hemost 2002; 28(s2): 041-048
DOI: 10.1055/s-2002-32315
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Symptomatic Venous Thromboembolism: Improving Outcomes

Harry R. Büller
  • Department of Vascular Medicine, Academic Medical Center at the University of Amsterdam, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
19 June 2002 (online)

    Permissions and Reprints

ABSTRACT

Antithrombotic therapy with unfractionated heparin (UFH) and warfarin for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) became widely accepted in the early 1960s. Subsequent clinical trials have focused on the importance of early intravenous UFH in the treatment of venous thromboembolic events, the method of heparin administration, the importance of rapid anticoagulation to prevent recurrent venous thromboembolism (VTE), and the optimal duration of UFH administration. Low-molecular-weight heparin (LMWH) represents a significant advance over UFH therapy for VTE. Developed in the late 1980s, LMWH has become an excellent alternative to UFH because it offers superior efficacy and safety, improved pharmacokinetics, longer half-life, and once- or twice-daily subcutaneous administration without the need for laboratory monitoring. Fondaparinux is the first of a new class of antithrombotic agents that targets factor Xa. Based on studies of the heparin binding site of antithrombin, this novel pentasaccharide has superior pharmacokinetics and bioavailability when compared with LMWH and can be administered once daily. Studies in patients undergoing major orthopedic surgery and in those with proximal DVT indicate that the efficacy and safety of fondaparinux may represent an improvement over those of LMWH.

KEYWORDS

Factor Xa inhibitor - fondaparinux - heparin - low-molecular-weight heparin - venous thromboembolism

REFERENCES

  • 1 Anderson Jr A F, Wheeler H B. Physician practices in the management of venous thromboembolism: a community-wide survey.  J Vasc Surg . 1992;  16 707-714
    PubMedGoogle Scholar
  • 2 Geerts W H, Heit J A, Clagett G P. Prevention of venous thromboembolism.  Chest . 2001;  119(suppl) 132S-175S
    CrossrefPubMedGoogle Scholar
  • 3 Brandjes D PM, Büller H R, Heijboer H. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.  Lancet . 1997;  349 759-762
    CrossrefPubMedGoogle Scholar
  • 4 Siddique R M, Siddique M I, Connors Jr F A, Rimm A A. Thirty-day case-fatality rates for pulmonary embolism in the elderly.  Arch Intern Med . 1996;  156 2343-2347
    CrossrefPubMedGoogle Scholar
  • 5 Raskob G E, Hull R D. Diagnosis of pulmonary embolism.  Curr Opin Hematol . 1999;  6 280-284
    CrossrefPubMedGoogle Scholar
  • 6 Line B R. Pathophysiology and diagnosis of deep venous thrombosis.  Semin Nucl Med . 2001;  31 90-101
    CrossrefPubMedGoogle Scholar
  • 7 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet . 1999;  353 1167-1173
    CrossrefPubMedGoogle Scholar
  • 8 Goldhaber S Z. Pulmonary embolism.  N Engl J Med . 1998;  339 93-104
    CrossrefPubMedGoogle Scholar
  • 9 Moser K M, LeMoine J R. Is embolic risk conditioned by location of deep venous thrombosis?.  Ann Intern Med . 1981;  94 439-444
    PubMedGoogle Scholar
  • 10 Huisman M V, Büller H R, ten Cate W J. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis.  Chest . 1989;  95 498-502
    CrossrefPubMedGoogle Scholar
  • 11 Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation.  Vasa . 2001;  30 195-204
    PubMedGoogle Scholar
  • 12 Brandjes D P, Heijboer H, Büller H R. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  327 1485-1489
    CrossrefPubMedGoogle Scholar
  • 13 Hyers T M, Agnelli G, Hull R D. Antithrombotic therapy for venous thromboembolic disease.  Chest . 2001;  176S-193S
    PubMedGoogle Scholar
  • 14 Barritt D W, Jordan S C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial.  Lancet . 1960;  1 1309-1312
    PubMedGoogle Scholar
  • 15 Kernohan R J, Todd C. Heparin therapy in thromboembolic disease.  Lancet . 1966;  1 621-623
    PubMedGoogle Scholar
  • 16 Alpert J S, Smith R, Carlson J. Mortality in patients treated for pulmonary embolism.  JAMA . 1976;  236 1477-1480
    CrossrefPubMedGoogle Scholar
  • 17 Kanis J A. Heparin in the treatment of pulmonary thromboembolism.  Thromb Diath Haemorrh . 1974;  32 519-527
    PubMedGoogle Scholar
  • 18 Hull R D, Raskob G E, Hirsh J. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.  N Engl J Med . 1986;  315 1109-1114
    CrossrefPubMedGoogle Scholar
  • 19 Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  N Engl J Med . 1997;  337 663-669
    CrossrefPubMedGoogle Scholar
  • 20 Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med . 1996;  334 677-681
    CrossrefPubMedGoogle Scholar
  • 21 Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
    CrossrefPubMedGoogle Scholar
  • 22 Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med . 1997;  337 657-662
    CrossrefPubMedGoogle Scholar
  • 23 Hull R D, Raskob G E, Brant R F. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism.  Arch Intern Med . 2000;  160 229-236
    CrossrefPubMedGoogle Scholar
  • 24 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.  N Engl J Med . 1972;  287 324-327
    CrossrefPubMedGoogle Scholar
  • 25 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.  Arch Intern Med . 1997;  157 2317-2321
    CrossrefPubMedGoogle Scholar
  • 26 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.  N Engl J Med . 1990;  322 1260-1264
    PubMedGoogle Scholar
  • 27 Hirsh J, Warkentin T E, Shaughnessy S G. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest . 2001;  119(suppl) 64S-94S
    CrossrefPubMedGoogle Scholar
  • 28 Fabris F, Luzzatto G, Stefani P M. Heparin-induced thrombocytopenia.  Haematologica . 2000;  85 72-81
    PubMedGoogle Scholar
  • 29 Prandoni P, Lensing A WA, Büller H R. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.  Lancet . 1992;  339 441-445
    CrossrefPubMedGoogle Scholar
  • 30 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  326 975-982
    CrossrefPubMedGoogle Scholar
  • 31 Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.  Thromb Haemost . 1994;  71 300-304
    PubMedGoogle Scholar
  • 32 Muir J M, Hirsh J, Weitz J I. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.  Blood . 1997;  89 3236-3242
    PubMedGoogle Scholar
  • 33 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1330-1335
    CrossrefPubMedGoogle Scholar
  • 34 Rocha E, Martinez-González M A, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis?.  <~>A meta-analysis. Haematologica . 2000;  85 935-942
    PubMedGoogle Scholar
  • 35 Dolovich L R, Ginsberg J S, Douketis J D, Holbrook A M, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism.  Arch Intern Med . 2000;  160 181-188
    CrossrefPubMedGoogle Scholar
  • 36 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials.  Ann Intern Med . 1999;  130 800-809
    CrossrefPubMedGoogle Scholar
  • 37 Bijsterveld N R, Hettiarachchi R, Peters R. Low-molecular weight heparins in venous and arterial thrombotic disease.  Thromb Haemost . 1999;  139-147
    PubMedGoogle Scholar
  • 38 van der Heijden F J, Prins M H, Büller H R. Low-molecular-weight heparins: are they interchangeable?.  Haemostasis . 2000;  148-157
    PubMedGoogle Scholar
  • 39 van Boeckel A A C, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics.  Angew Chem Int Ed Engl . 1993;  32 1671-1690
    PubMedGoogle Scholar
  • 40 Donat F, Duret J P, Santoni A. Pharmacokinetics of Org31540/SR90107A in young and elderly healthy subjects: a highly favourable pharmacokinetic profile [abstract P3094]. Thromb Haemost 2001;July(suppl). Available on CD-ROM published by Excerpta Medica Medical Communications
    Google Scholar
  • 41 The REMBRANDT Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation.  Circulation . 2000;  102 2726-2731
    PubMedGoogle Scholar
  • 42 Breddin H K, Kakkar V V, Hach-Wunderle V, Nakov R. Treatment of acute DVT with the low molecular weight heparin (LMWH) reviparin: results of the CORTES-study (Abst).  Blood . 1999;  94 30
    PubMedGoogle Scholar
  • 43 Decousus H, Leizorovicz A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.  N Engl J Med . 1998;  338 409-415
    CrossrefPubMedGoogle Scholar
  • 44 Harenberg J, Schmidt J A, Koppenhagen K. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis.  Thromb Haemost . 2000;  83 652-656
    PubMedGoogle Scholar
  • 45 Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin℗ with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  72 186-190
    PubMedGoogle Scholar
  • 46 Lopaciuk S, Meissner A J, Filipecki S. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.  Thromb Haemost . 1992;  68 14-18
    PubMedGoogle Scholar
  • 47 Luomanmäki K, Grankvist S, Hallert C. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.  J Intern Med . 1996;  240 85-92
    CrossrefPubMedGoogle Scholar
  • 48 Simonneau G, Charbonnier B, Decousus H. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.  Arch Intern Med . 1993;  153 1541-1546
    CrossrefPubMedGoogle Scholar
      >